1 Le Thésaurus est un travail collaboratif sous égide de la Fédération Francophone de Cancérologie Digestive (FFCD), de la Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), du Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR), de la Société Française de Chirurgie Digestive (SFCD), de la Société Française de Radiothérapie Oncologique (SFRO) et de la Société Nationale Française de Gastroentérologie (SNFGE). Chapitre : 9 Cancer du pancréas Date de cette version : 11/02/2011 Date de dernière mise à jour à vérifier sur www.tncd.org M ise en garde Du fait de l'actualisation fréquente du TNCD, l'utilisation de ce document imprimé impose de vérifier qu'une version plus récente n'a pas été mise à disposition sur le site. Si la date ci-dessus remonte à plus d'un an, ce document n'est certainement plus à jour et doit être remplacé par un nouveau.
23
Embed
Cancer du pancréas 11/02/2011 - Portail ProInfosCancer · nouveau. 2 9. ... En effet, chez un malade qui a un ictère cholestatique (ictère cutanéo- ... opératoire il est préférable
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Le Thésaurus est un travail collaboratif sous égide de la Fédération
Francophone de Cancérologie Digestive (FFCD), de la Fédération
Nationale des Centres de Lutte Contre le Cancer (FNCLCC), du Groupe
Coopérateur multidisciplinaire en Oncologie (GERCOR), de la Société
Française de Chirurgie Digestive (SFCD), de la Société Française de
Radiothérapie Oncologique (SFRO) et de la Société Nationale Française
de Gastroentérologie (SNFGE).
Chapitre : 9
Cancer du pancréas
Date de cette version :
11/02/2011
Date de dernière mise à jour à vérifier sur www.tncd.org
M ise en garde
Du fait de l'actualisation fréquente du TNCD,
l'utilisation de ce document imprimé impose de vérifier
qu'une version plus récente
n'a pas été mise à disposition sur le site.
Si la date ci-dessus remonte à plus d'un an, ce document
n'est certainement plus à jour et doit être remplacé par un
2. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus
folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8;304(10):1073-81.
3. Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9
4. Huguier M, Mason N. Treatment of cancer of the exocrine pancreas. Am J Surg 1999;177:257-65.
5. Palazzo L, Roseau G, Gayet B, Vilgrain V, Belghiti J, Fékété F et al. Endoscopic ultrasonography in the diagnosis and staging of pancreatic adenocarcinoma. Results of a prospective study with comparison to ultrasonography and CT scan. Endoscopy 1993 ; 25 :
143-50. 6. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I et al. Pancreatic
tumors : comparison of dual-phase helical CT and endoscopic sonography. Am J Roentgenol
(AJR) 1998 : 170 : 1315-22.
7. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer : recent
controversies and current practice. Gastroenterology 2005; 128: 1626-41. 8. Gallix BP. Magnetic resonance imaging of the pancreas: value and limits. Gastroenterol Clin
Biol. 2003;27 (5 Suppl):B57-62.
9. Pery C, Meurette G, Ansquer C, Frampas E, Regenet N. Role and limitations of (18)F-FDG
positron emission tomography (PET) in the management of patients with pancreatic lesions. J Gastroenterol. 2010 Jul 16. [Epub ahead of print]
10. Maire F, Sauvanet A, Trivin F, Hammel P, O'Toole D, Palazzo L, et al.. Staging of pancreatic
head adenocarcinoma with spiral CT and endoscopic ultrasonography: an indirect evaluation of the usefulness of laparoscopy. Pancreatology. 2004;4:436-40.
11. Voss M, Hammel P, Molas G, Palazzo L, Dancour A, O’Toole D, et al. Diagnostic value of endoscopic ultrasound fine needle aspiration in the diagnosis of solid pancreatic masses. Gut 2000 ; 46 : 244-9.
12. Neuhaus P, Riess H, Post S, Gellert K, Langrehr J, Ridwelski K et al. CONKO-001; Final results of the randomized, prospective, multicenter phase III trial of Adjuvant chemotherapy with gemcitabine vs observation in patients with resected pancreatic cancer (PC). J Clin Oncol
26:15s, 2008 (suppl; abstr 4504) 13. Moutardier V, Giovannini M, Magnin V, Viret F, Lelong B, Delpero JR. How to improve
treatment of resectable pancreatic adenocarcinomas? Surgical resection, histopathological
14. Furhrman GM, Charnsangavej C, Abbruzzese JL, Cleary KR, Martin RG, Fenoglio CJ, et al.
Thin-section, contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994, 167: 104-13
15. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in
the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009 May 1;27(13):2269-77
16. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe et al.Adjuvant
Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II
Study. J Clin Oncol 2010;28:4450-4456.
17. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, et al. BL. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001, 5 : 121-30.
18. Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009 10;27(17):2855-62
19. Lin PW, Lin YJ. Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy. Br J Surg 1999;86:603-7.
20. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, et al. Standart versus extended lymphadenectomy associated with pancreatectomy in the surgical treatment of
adenocarcinoma of the head of the pancreas. Ann Surg 1998, 228 :508-517.
21. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003 27;349:2117-27.
22. Moss AC, Morris E, Leyden J, Mac Mathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cochrane
Database Syst Rev. Cancer Treat Rev 2007,33(2):213_21
23. Heslin MJ, Brooks AD, Hochwald SN, Harrison LE, Blumgart LH, Brennan MF. A preoperative biliary stent is associated with increased complications after
pancreatoduodenectomy. Arch Surg. 1998 ;133:149-54. 24. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive
jaundice. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing
obstructive jaundice. Ann Surg. 2002 ;236:17-27. Review.
25. Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman JA et al. Is
prophylactic gastrojejunostomy indicated for unresectable periampullary cancer ? A prospective randomized trial. Ann Surg 1999;230:322-30.
26. Maire F, Hammel P, Ponsot P, Aubert A, O'Toole D, Hentic O, et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol 2006;101:735-42
27. Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, et al. Fédération Francophone
de Cancérologie Digestive. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-
CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomized strategic phase III trial (FFCD 0301) ; Gut. 2010 Nov;59(11):1527-34
28. Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud V, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic
adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 28:15s, 2010 (suppl; abstr 4010)
29. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, et al.
Advances in counselling and surveillance of patients at risk for pancreatic cancer.Participants
of the Fourth International Symposium of Inherited Diseases of the Pancreas. Gut 2007;10:1460-9
30. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase
III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with
31. Neoptolemos JP, Dunn JA, Moffit D, Berger H, Lacaine F, Link K et al. ESPAC-1: a european, randomized study to assess the roles of adjuvant chemotherapy (5-FU+ folinic Acid) and adjuvant chemoradiation in resectable pancreatic cancer. Lancet 2001 ;358 :1576-
85. 32. J.P. Neoptolemos, D.D. Stocken, H Fries, C. Bassi, J.A. Dunn, H Hickey, H. Beger, L.
Fernandez-Cruz, C. Dervernis, F. Lacaine, M. Falconi, P. Pederzoli, A. Pap, D. Spooner, D.J. Kerr, M. Büchler, for the European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med
2004;350:1200-1210
33. Van der Gaag NA, Rauws EA, van Eijck CH et al. Preoperative biliary drainage for cancerof
the head of the pancreas. N Engl J Med 2010 ;362 :129-37 34. Lacaine F. Chirurgie palliative et de dérivation. In LacaineF et Sauvanet A. Chirurgie du
pancréas et de la rate. Elsevier-Masson. Paris, 2009. pp 78-84 35. Delpero JR, Paye F, Bachellier Ph, Boher JM. Cancer du Pancréas. Monographies de
l’Association Française de Chirurgie. Rapport présenté au 112e Congrès français de chirurgie. Paris, 6-8 octobre 2010. Wolters Kluwer France, 2010
36. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis
of response and resection percentages.PLoS Med. 2010 20;7(4):e1000267
22
37. Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, et al. Hepatic ressection for noncolorectal nonendocrine metastases : analysis of 1452 patients and development of
prognostic model. Ann Surg 2006; 244(4):524-35
38. Oettle H, Post S, Neuhaus P, Gellert k, Langrehr J, Ridwelski K et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 ;297(3):267-77.
39. Turinni O, Viret F, Moureau Zabotto L, Guiramand J, Moutardier V, Lelong B et al.
Neoadjuvant chemotherapy for initially locally advanced head pancreatic adenocarcinoma.
Eur J Surg Oncol 2009; 35:1306-11 40. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Gorner M et al. A randomized trial in
patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study.
J Clin Oncol 26:13s, 2008_ (suppl; abstr 4508) 41. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolf RA et al. Long term survival after
multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol
2009;16: 836-47
42. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously
unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7:766-72. 43. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK et al.
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
44. Burris HA3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997;15:2403-13.
45. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R et al.
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients3402with pancreatic adenocarcinoma.. J Clin Oncol. 21: 3402-8, 2003
46. Louvet C, Labianca R, Hammel P, Lledo G, de Braud F, André T, et al. GemOx (Gemcitabine
+ Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma : final results of the GERCOR /GISCAD Intergroup Phase III. J Clin Oncol 2005 20;23:3509-16.
47. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams
RA, Hruban RH. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002, 236, 355-66.
48. Moore MJ, Golstein D, Hamm J, A. Figer, J. Hecht, S. Gallinger et al. Erlotinib improve
survival when added to gemcitabine in patients with advanced pancreatic adenocarcima. A
phase III trial. The National Cancer of Canada Clinical Trials Group (NCI-CTG). J Clin Oncol
2007 20;25:1960-6. 49. Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, et al.
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal
lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J Gastrointest Surg. 2005;9(9):1191-204; discussion 1204-6.
50. Luque de Leon E, Tsiotos GG, Balsiger B, Barnwell J,Burgart LJ, Sarr MG. Staging laparoscopy for pancreatic cancer should be used to select the best means of palliation and not
only to maximize the resectability rate. J Gastrointest Surg 1999 ; 3 : 111-7. 51. Pancreatic cancer and thrombosis. Highlights from the "2010 ASCO Annual Meeting".
Chicago, IL, USA. June 4-8, 2010. Shah MM, Saif MW. JOP. 2010 Jul 5;11(4):331-3. Review
53. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma. An analysis of 181 patients enrolled in GERCOR phase II and III studies. J Clin Oncol. 2007
20;25(3):326-31
23
54. Chauffert B, F Mornex, F Bonnetain, JP Triboulet, O Bouche, E Mitry et al. Phase III comparing initial chemotherapy (intermitent cisplatin and infusional 5FU) followed by
gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer : a
FFCD-SFRO study. Proc Am Clin Oncol 2006;24:180s (abstr 4008).
55. Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Bellannee G, Brunet R, et al.
Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.J Am Coll Surg. 2005 Sep;201(3):359-65.
56. Heinemann V, Quietzsch D, Gieseler M, Gonnermann M, Schonekas A, Rost H et al.
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006 ; 20:3946-52.
57. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al.. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion)
compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma
E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009
10;27(23):3778-85.
58. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials:
evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced
pancreatic cancer. BMC Cancer. 2008 28;8:82. 59. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al Phase III
randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 27:5513-8.
60. Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, et al. Clinical
benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine
plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-- SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008;26(22):3695-701
61. Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaner I, et al. Oxaliplatin/folinic acid/5-
fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in
second-line therapy of gemcitabine-refractory advanced pancreatic cancer. Proc Am Clin Oncol 2005; 23:3158s (abstr 4031).
62. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg.
2000;135(4):409-14; discussion 414-5.
63. Barreiro CJ, Lillemoe KD, Koniaris LG, Sohn TA, Yeo CJ, Coleman J, Fishman EK,
Cameron JL. Diagnostic laparoscopy for periampullary and pancreatic cancer: what is the true benefit? J Gastrointest Surg. 2002;6(1):75-81.
64. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P et al. Induction
chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for
optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110(1):47-55.
65. Gebbia V, Maiello E, Giuliani F, Borsellino N, Caruso M, Di Maggio G et al, Second-line
chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical
practice. Ann Oncol. 2007;18 Suppl 6:vi124-7.
66. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A et al.: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299 (9): 1019-26.
67. Kindler HL, Niedzwiechi D, Hollis D, Oraefo E, Schrag H, Hurvitz h et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus Gemcitabine plus placebo in pts with advanced pancreatic cancer (PC): phase III trial
of the Cancer and Leukemia Group B (CALGB). J Clin Oncol. 2010;28(22):3617-22 68. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, et al. Phase III study
comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.J Clin